Articles From: ON Semiconductor Announces New Capital Allocation Policy; Board of Directors Approves $1 Billion Share Repurchase Program to Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency


ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, today announced that its Board of Directors has approved a capital allocation policy under which the company intends to return approximately 80 percent of free cash flow less repayments of long-term debt to shareholders, subject to a variety of factors, including the company’s strategic plans, market and economic conditions, and Board of Directors’ discretion.
Sign-up for ON Semiconductor Announces New Capital Allocation Policy; Board of Directors Approves $1 Billion Share Repurchase Program investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, has entered into a licensing/development agreement with ICs LLC in order to bring application specific integrated circuits (ASICs) to market which are resilient to radiation effects.
Sign-up for ON Semiconductor Collaborates with ICs LLC to Develop Radiation Hardened ASICs for Military and Aerospace Applications investment picks
VISION Trade Fair – Booth 1C82 – ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, has introduced two new higher resolutions CMOS image sensors to its successful PYTHON product family.
Sign-up for ON Semiconductor Expands PYTHON CMOS Image Sensor Family to Address Higher Resolution Industrial and Traffic Applications investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, announces two new series of power factor corrected (PFC) offline Ac-Dc drivers for high performance LED lighting applications.
Sign-up for ON Semiconductor Introduces Two New Series of Power Factor Corrected Ac-Dc Drivers for LED Lighting Applications investment picks
VISION Trade Fair – Booth 1C82 – ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, has set a new benchmark in low-light imaging for industrial markets with the introduction of a new class of CCD image sensor technology.
Sign-up for ON Semiconductor Re-Defines Low-Light Imaging with New Class of CCD Image Sensors investment picks
ON Semiconductor Corporation (Nasdaq: ONNN): For the third quarter of 2014, highlights include: ON Semiconductor Corporation (Nasdaq: ONNN), driving energy efficient innovation, today announced that total revenues in the third quarter of 2014 were $833.5 million, up approximately 10.0 percent compared to the second quarter of 2014.
Sign-up for ON Semiconductor Reports Third Quarter 2014 Results investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficient innovations, announced today that it will host its Financial Analyst Day in Scottsdale, Arizona on February 26, 2015, starting at 8:00 a.m. MST.
Sign-up for ON Semiconductor to Host Financial Analyst Day investment picks
electronica 2014 – Hall A5, Stand 225 – ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, introduces two new devices for use in vehicle lighting systems.
Sign-up for ON Semiconductor Unveils New Devices for Automotive Lighting Applications at Electronica 2014 investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, has introduced a family of affordable, precision CMOS operational amplifiers (op amps) that deliver zero drift operation and industry leading quiescent current for front-end amplifier circuits and power management designs.
Sign-up for ON Semiconductor Unveils New Family of Ultra-Low Power Precision Operational Amplifiers investment picks
ON Semiconductor's stock (ONNN) rose 3% in premarket trade Monday, after the chipmaker announced a new $1 billion share repurchase program.
Sign-up for ON Semiconductor's stock rises after $1 billion buyback annoucement investment picks
ON Semiconductor (Nasdaq: ONNN ), driving energy efficiency innovations, has introduced its latest high performance CMOS image sensor targeted for use in advanced video security cameras.
Sign-up for ON Semiconductor’s New 2.1 Megapixel CMOS Image Sensor Delivers High Performance 1080p HDR Video for Security Cameras investment picks
http://media.marketwire.com/attachments/201311/68577_OTIlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160755&ProfileId=051205&sourceType=1 ROSH PINA, ISRAEL --
Sign-up for On Track Innovations (oti) Announces Pricing of Public Offering of Ordinary Shares investment picks
http://media.marketwire.com/attachments/201311/68577_OTIlogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160332&ProfileId=051205&sourceType=1 ROSH PINA, ISRAEL --
Sign-up for On Track Innovations (oti) Announces Proposed Public Offering investment picks
2014/11/28
By Marek Fuchs, MarketWatch Things just got unreal, from shaky economic stats to GM deathtraps A sheaf of economic statistics came out over the course of our shortened week and, depending on which you seized upon, the economy looked like either a rising Phoenix or a wounded duck.
Sign-up for On Wall Street, a week of epic fails investment picks
2014/10/27
Onco360, one of the nation’s largest independent providers of oncology pharmacy services, today announced that Paul Jardina has been named President and Chief Executive Officer.
Sign-up for Onco360 Appoints Paul Jardina as President and Chief Executive Officer investment picks
2015/1/5
Onco360, one of the nation’s largest independent providers of Oncology Pharmacy services, today announced that it has been selected by Bayer AG (“Bayer”) as a limited distribution pharmacy network participant for two of its leading oncology medications, Nexavar ® (sorafenib) and Stivarga ® (regorafenib). With the addition of these two medications, Onco360’s industry-leading oncology medication portfolio now comprises nearly 40 limited distribution products.
Sign-up for Onco360 Chosen by Bayer as Limited Distribution Pharmacy Provider investment picks
2014/12/1
Onco360, one of the nation’s largest independent providers of Oncology Pharmacy services, today announced that it has been selected as a limited distribution pharmacy network participant by Pfizer Inc. (“Pfizer”), and can immediately begin dispensing Bosulif ® (bosutinib), Inlyta ® (axitinib), Sutent ® (sunitinib), and Xalkori ® (crizotinib). With the addition of these four medications, Onco360’s industry-leading oncology medication portfolio now comprises nearly 40 limited distribution products.
Sign-up for Onco360 Selected by Pfizer as Limited Distribution Pharmacy Provider; Expands Onco360’s Industry-Leading Portfolio to Nearly 40 Products investment picks
Exploratory Analysis Shows Addition of 600mg Apatorsen to Standard of Care Chemotherapy Resulted in 50 Percent Reduction in Risk of Death in Patients with Lower Performance Status Phase 2 Trial Informs Appropriate Apatorsen Dosing and Patient Population for Future Trials in Metastatic Bladder Cancer BOTHELL, Wash.
Sign-up for OncoGenex Announces Results from the Phase 2 Borealis-1™ Trial of Apatorsen in the Treatment of Metastatic Bladder Cancer investment picks
AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer investment picks
OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer Canada NewsWire AFFINITY Trial to Continue as Planned Following Completion of Interim Futility Analysis BOTHELL, Wash.
Sign-up for OncoGenex Announces Update on Phase 3 AFFINITY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer investment picks
2014/10/30
Conference call to be held on Thursday, October 30, 2014 at 4:30 p.m. Eastern Time BOTHELL, Wash.
Sign-up for OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014 investment picks
BOTHELL Wash.
Sign-up for OncoGenex to Regain Rights to Custirsen from Teva investment picks
OncoGenex to Regain Rights to Custirsen from Teva Canada NewsWire BOTHELL Wash.
Sign-up for OncoGenex to Regain Rights to Custirsen from Teva investment picks
2014/12/22
Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers Canada NewsWire CALGARY , Dec.
Sign-up for Oncolytics Biotech® Inc. Announces Filing for Orphan Designation with the EMA for Pancreatic and Ovarian Cancers investment picks
2014/11/4
CALGARY , Nov.
Sign-up for Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: ON Semiconductor Announces New Capital Allocation Policy; Board of Directors Approves $1 Billion Share Repurchase Program to Oncolytics Biotech® Inc. Announces Receipt of Nasdaq Notice of Deficiency
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent